Tekla Life Sciences Investors Stock Forecast, Price & News

Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions

What stocks does MarketBeat like better than Tekla Life Sciences Investors?

Wall Street analysts have given Tekla Life Sciences Investors a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tekla Life Sciences Investors wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 17,500 shares, a decline of 61.8% from the September 15th total of 45,800 shares. Based on an average daily volume of 68,700 shares, the short-interest ratio is presently 0.3 days.
View Tekla Life Sciences Investors' Short Interest.

How has Tekla Life Sciences Investors' stock been impacted by Coronavirus (COVID-19)?

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HQL stock has increased by 39.1% and is now trading at $20.66.
View which stocks have been most impacted by COVID-19.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors declared a quarterly dividend on Wednesday, August 18th. Shareholders of record on Friday, August 27th will be given a dividend of $0.43 per share on Thursday, September 30th. This represents a $1.72 annualized dividend and a dividend yield of 8.33%. The ex-dividend date is Thursday, August 26th. This is a positive change from Tekla Life Sciences Investors's previous quarterly dividend of $0.41.
View Tekla Life Sciences Investors' dividend history.

Is Tekla Life Sciences Investors a good dividend stock?

Tekla Life Sciences Investors pays an annual dividend of $1.67 per share and currently has a dividend yield of 8.06%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Tekla Life Sciences Investors' dividend history.

Who are Tekla Life Sciences Investors' key executives?

Tekla Life Sciences Investors' management team includes the following people:

• Dan Omstead, President, Chief Executive Officer & Trustee
• Jason C. Akus, Senior Vice President-Research
• Timothy L. Gasperoni, Senior Vice President-Research
• Laura F. Woodward, Secretary, Treasurer & Chief Compliance Officer

Who are some of Tekla Life Sciences Investors' key competitors?

Some companies that are related to Tekla Life Sciences Investors include WisdomTree Emerging Markets High Dividend Fund (DEM), Goldman Sachs BDC (GSBD), PIMCO Corporate & Income Opportunity Fund (PTY), Royce Value Trust (RVT), Tri-Continental (TY), Liberty All-Star Equity Fund (USA), The Gabelli Equity Trust (GAB), iShares MSCI Australia ETF (EWA), Boulder Growth & Income Fund (BIF), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), Tekla Healthcare Investors (HQH), Central Securities (CET), General American Investors (GAM), AllianceBernstein Global High Income Fund (AWF) and Aberdeen Asia-Pacific Income Fund (FAX).
View all of HQL's competitors.

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Who are Tekla Life Sciences Investors' major shareholders?

Tekla Life Sciences Investors' stock is owned by many different institutional and retail investors. Top institutional shareholders include NEXT Financial Group Inc (0.13%), Private Advisor Group LLC (0.10%) and FNY Investment Advisers LLC (0.01%).
View institutional ownership trends for Tekla Life Sciences Investors.

Which major investors are buying Tekla Life Sciences Investors stock?

HQL stock was purchased by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, NEXT Financial Group Inc, and FNY Investment Advisers LLC.
View insider buying and selling activity for Tekla Life Sciences Investors or or view top insider-buying stocks.

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $20.66.

How much money does Tekla Life Sciences Investors make?

Tekla Life Sciences Investors has a market capitalization of $501.60 million.

What is Tekla Life Sciences Investors' official website?

The official website for Tekla Life Sciences Investors is www.teklacap.com.

Where are Tekla Life Sciences Investors' headquarters?

Tekla Life Sciences Investors is headquartered at 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at (617) 772-8500 or via email at [email protected].